{
    "key_points": [
        "French Haute Autorite de Sante (HAS) advises against Moderna COVID-19 vaccine for under 30s due to 'very rare' myocarditis risks.",
        "HAS highlights that the risk of myocarditis is five times lesser with Pfizer's Comirnaty jab compared to Moderna's Spikevax for under 30s.",
        "The recommendation by HAS is based on recent data and a French study published on Monday.",
        "European Union's drug regulator, EMA, approved Moderna's booster vaccine for all over 18s, six months after the second dose.",
        "EMA found a possible link between rare inflammatory heart conditions and mRNA COVID-19 vaccines from both Pfizer and Moderna.",
        "Despite the finding, EMA states the benefits of mRNA vaccines in preventing COVID-19 outweigh the risks.",
        "HAS's recommendation applies to the Moderna vaccine's use as a first, second, or third 'booster' dose for under 30s.",
        "For those aged over 30, HAS recommends the Moderna vaccine, citing its slightly superior effectiveness.",
        "The HAS's recommendation will remain valid until more scientific data on the issue is available.",
        "The U.S. regulators and the World Health Organization echo EMA's view on the benefits of mRNA vaccines."
    ],
    "spokespersons": [],
    "article_type": "general reporting",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}